Sanofi-Aventis to pay ex-CEO €6.7 million
This article was originally published in Scrip
Gerard Le Fur, the ex-CEO of Sanofi-Aventisis to receive a total of €6.7 million as part of his termination agreement. Although Mr Le Fur fulfilled the criteria for receiving the full severance pay available to him, he and Sanofi-Aventis agreed that he would only receive half of this amount as he had only held the position of CEO for two years. He will therefore be paid €2.7 million in an up-front termination benefit.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.